MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

Search

Cytek Biosciences Inc

Atvērts

SektorsVeselības aprūpe

4.6 -2.75

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.45

Max

4.6899999999999995

Galvenie mērījumi

By Trading Economics

Ienākumi

-39M

-44M

Pārdošana

9.8M

62M

Peļņas marža

-70.929

Darbinieki

702

EBITDA

4M

-263K

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+35.87% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

20M

581M

Iepriekšējā atvēršanas cena

7.35

Iepriekšējā slēgšanas cena

4.6

Ziņu noskaņojums

By Acuity

50%

50%

168 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Cytek Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. apr. 20:44 UTC

Peļņas

Costco Reports 11% Growth in March Sales

2026. g. 8. apr. 23:51 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. apr. 23:51 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

2026. g. 8. apr. 23:36 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026. g. 8. apr. 22:56 UTC

Tirgus saruna

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

2026. g. 8. apr. 22:45 UTC

Tirgus saruna

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

2026. g. 8. apr. 22:17 UTC

Tirgus saruna

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

2026. g. 8. apr. 21:52 UTC

Galvenie ziņu notikumi

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

2026. g. 8. apr. 21:24 UTC

Peļņas

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

2026. g. 8. apr. 21:01 UTC

Galvenie ziņu notikumi

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

2026. g. 8. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 8. apr. 20:43 UTC

Iegādes, apvienošanās, pārņemšana

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

2026. g. 8. apr. 20:43 UTC

Iegādes, apvienošanās, pārņemšana

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

2026. g. 8. apr. 20:43 UTC

Iegādes, apvienošanās, pārņemšana

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

2026. g. 8. apr. 20:42 UTC

Iegādes, apvienošanās, pārņemšana

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

2026. g. 8. apr. 20:42 UTC

Iegādes, apvienošanās, pārņemšana

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

2026. g. 8. apr. 20:42 UTC

Iegādes, apvienošanās, pārņemšana

Oracle Responds to TRC Cap Mini-Tender Offer

2026. g. 8. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. apr. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

2026. g. 8. apr. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

2026. g. 8. apr. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

2026. g. 8. apr. 19:44 UTC

Peļņas

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

2026. g. 8. apr. 19:16 UTC

Tirgus saruna

Hogs Follow Cutout Prices Lower -- Market Talk

2026. g. 8. apr. 19:02 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 8. apr. 19:02 UTC

Tirgus saruna

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

2026. g. 8. apr. 18:58 UTC

Tirgus saruna

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

2026. g. 8. apr. 18:51 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. apr. 18:51 UTC

Tirgus saruna

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

2026. g. 8. apr. 18:14 UTC

Galvenie ziņu notikumi

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

2026. g. 8. apr. 18:05 UTC

Galvenie ziņu notikumi

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Cytek Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

35.87% augšup

Prognoze 12 mēnešiem

Vidējais 6.25 USD  35.87%

Augstākais 7.5 USD

Zemākais 5 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cytek Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

1

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

3.7 / 3.8Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

168 / 349 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat